The impact of AMP-activated protein kinase (AMPK)-instrumented HbA1c reduction (%) on breast and prostate cancer using Mendelian randomization
| Nine single-nucleotide polymorphisms | Data sets | Inverse variance weighting with fixed effects | |
| OR | 95% CI | ||
| Breast cancer (overall) | Breast Cancer Association Consortium | 0.70 | 0.29 to 1.69 |
| Breast cancer (estrogen receptor +ve) | Breast Cancer Association Consortium | 0.77 | 0.27 to 2.20 |
| Breast cancer (estrogen receptor −ve) | Breast Cancer Association Consortium | 1.69 | 0.34 to 8.32 |
| Breast cancer (overall) | UK Biobank | 1.28 | 0.21 to 7.87 |
| Prostate cancer | Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome consortium | 0.60 | 0.19 to 1.85 |